Stock Information
symbol line chart

RSLSReShape Lifesciences Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Dan W. Gladney

Location

California, USA

Exchange

Nasdaq

Website

https://www.enteromedics.com

Summary

EnteroMedics, Inc.

Company Info

CEO

Dan W. Gladney

Location

California, USA

Exchange

Nasdaq

Website

https://www.enteromedics.com

Summary

EnteroMedics, Inc.

AI Insights for RSLS
5 min read

Quick Summary

ReShape Lifesciences Inc., historically known through EnteroMedics and related obesity-device assets, is a small medical-device company focused on treatments for obesity, metabolic disease, and gastrointestinal disorders. Its legacy technology base includes neuroblocking approaches intended to affect vagus-nerve signaling and help patients feel fuller, reduce hunger, and improve weight-management outcomes. The company has also been associated with bariatric and endoscopic weight-loss products, including devices used by physicians and obesity-care specialists rather than products sold directly as ordinary consumer goods. Its main customers are bariatric surgeons, gastroenterologists, hospitals, outpatient surgical centers, obesity clinics, and patients seeking device-based alternatives or complements to diet, medication, and surgery. The company is very small financially, with low revenue, negative earnings, limited employee scale, and a micro-cap market valuation, so its business profile is closer to a speculative development-stage or restructuring-stage healthcare company than a mature medical-device manufacturer.

Strengths

•

ReShape’s main strength is its historical focus on a large medical need, since obesity and metabolic disease remain major global healthcare challenges.

•

The company’s legacy neuroblocking and bariatric-device technologies provide differentiated intellectual-property and clinical-development experience in a specialized field.

•

Its small size can allow strategic flexibility, including mergers, restructurings, asset sales, or shifts into higher-priority healthcare areas.

•

The merger with Vyome Therapeutics may create a new investment narrative that is less dependent on the slow commercialization of legacy obesity devices.

•

The company also benefits from being publicly listed, which can provide access to capital markets if investor interest and regulatory compliance are maintained.

Key Risks

•

The company faces very high risk because it is small, historically unprofitable, and dependent on capital markets or strategic transactions.

•

Shareholders may experience dilution, reverse splits, or sharp price declines if financing is needed or if the merger does not create confidence.

•

Legacy obesity-device products face intense competition from drugs, surgical procedures, and better-capitalized medical-device companies.

•

Regulatory, clinical, reimbursement, and commercialization failures could prevent products from reaching meaningful adoption.

What to Watch

The only detailed quarterly financial data supplied in the dataset is for Q2 2021, so those figures should be treated as historical reference data rather than a current snapshot of the company’s latest financial condition.
In that historical quarter, ReShape generated operating revenue of about $1.242 million and total gross profit of about $599,000, while remaining unprofitable with total operating income of approximately negative $2.762 million and net income of approximately negative $2.63 million.
Basic and diluted EPS were both negative $2.25, and the company paid no dividend.
More recent company-specific developments referenced in the research are corporate-structure events rather than updated operating results: Vyome Therapeutics received Nasdaq approval for listing after its merger with ReShape Lifesciences, the combined company was expected to trade as Vyome Holdings under ticker HIND beginning August 15, 2025, and ReShape was completing a 1-for-4 reverse stock split in connection with the transaction.
Because no updated quarterly cash balance, revenue, or income-statement data is included in the provided dataset, investors should verify the latest SEC filings before relying on the historical Q2 2021 numbers.

Price Drivers

•

The stock price is primarily driven by speculation, corporate actions, liquidity, and investor sentiment rather than stable earnings.

•

The historical financial data provided shows very low revenue, negative operating income, negative net income, and negative EPS, which means traditional valuation support is limited.

•

Reverse stock splits, merger news, Nasdaq listing status, and changes in the company’s trading symbol can create sharp price movements independent of product sales.

•

The reported merger with Vyome Therapeutics and the transition toward Vyome Holdings under the ticker HIND are major drivers because investors may revalue the entity based on the new company’s pipeline and strategy rather than ReShape’s legacy obesity-device business.

•

Broader healthcare risk appetite, penny-stock momentum, biotech speculation, and volatility in low-float micro-cap names can also strongly affect the share price.

Recent News

•

Recent news indicates that Vyome Therapeutics received Nasdaq approval for listing after its merger with ReShape Lifesciences.

•

The combined company, Vyome Holdings, is expected to trade under the ticker HIND beginning at the open on August 15, 2025.

•

ReShape is completing a 1-for-4 reverse stock split in connection with the transaction, while the news states that post-merger ownership allocations will not change.

•

Vyome’s focus is on immuno-inflammatory diseases and U.S.-India healthcare innovation, which represents a strategic shift away from ReShape’s legacy identity as an obesity medical-device company.

•

Other recent news items referenced are mostly broader penny-stock, biotech, and healthcare-investing articles rather than direct operating updates for RSLS.

Market Trends

•

Several broader market trends affect ReShape and the combined Vyome Holdings story.

•

Obesity treatment is changing rapidly because GLP-1 and next-generation metabolic drugs have attracted enormous patient, physician, and investor attention.

•

At the same time, medical-device and biotech micro-caps remain highly speculative, with share prices often driven by catalysts, financing, reverse splits, exchange compliance, and retail trading momentum.

•

Healthcare investors are favoring companies with strong clinical data, clear regulatory pathways, and enough cash runway to reach milestones, which can disadvantage very small loss-making companies.

•

The merger trend among distressed or micro-cap healthcare firms may continue as companies seek Nasdaq listings, new pipelines, and renewed investor narratives.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on RSLS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show